MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report **1-800-533-1710**

Patient Name	Patient ID	Age	Gender	Order #
TEST,IMPLEMENTATION TESTING	321	56	F	R1056575
Ordering Phys Test,Pathologist				**DOB** 05/23/1956
Client Order # R1056575	**Account Information**			**Report Notes**
Collected 11/02/2012 06:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 11/02/2012 19:55				

Test	Flag	Results	Unit	Reference Value
HER2, Breast IHC, Automated			REPORTED 11/02/2012 11:26	
Accession Number		HR12-83		
Material:				
1 block SP12-677 A1				
Tissue:				
A:Testing				
Interpretation:				
HER2, Immunostain:				
Source: Breast, right needle biopsy, block SP12-677 A1				
HER2 protein overexpression is equivocal, score of 2+.				
Fluorescence in situ hybridization (FISH) for HER2 amplification will be performed and reported separately by the Division of Laboratory Genetics.				
Fixation: HER2 protein immunohistochemical (IHC) test results are only valid for non-decalcified paraffin embedded specimens fixed in 10% neutral buffered formalin within 1 hour of acquisition and fixed between 6 and 48 hours. Delay to fixation, under fixation or over fixation fall outside of CAP/ASCO guidelines and may affect these results. Fixation conditions for this specimen were indicated to be within the CAP/ASCO guidelines for HER2 testing.				
1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43				
Method: Testing is performed using FDA approved Ventana Pathway HER2 (4B5) rabbit monoclonal primary antibody and a proprietary detection system. Negative (HER2 score of 0), moderate expression (HER2 score of 1+), and high expression (HER2 score of 3+) controls are used. All controls show appropriate reactivity. Immunohistochemical stained slides are scanned using the Aperio ScanScope instrument. A technologist views the captured digital image and traces around areas of cancer to include at least 75% of the total invasive cancer within the image. The traced areas are analyzed using Aperio software, an FDA 510(k) cleared application for precise measurement of the level of HER2 protein on cell membranes of breast tumor cells. Membrane staining for HER2 protein in breast carcinoma is scored on a 0 to 3+ scale in accordance with CAP/ASCO guidelines. The Aperio data and corresponding slide are reviewed by a pathologist for final interpretation.				
SP Signing Pathologist:		See Below		
Result: 11/2/2012 11:25 Interpreted by: Pathologist X. Test, M.D.				
Report electronically signed by Debbie A. Postier				
Transcribed by: dap07 11/2/2012 11:25:38				

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report **1-800-533-1710**

Patient Name	Patient ID	Age	Gender	Order #
TEST,IMPLEMENTATION TESTING	321	56	F	R1056575
Ordering Phys Test,Pathologist				**DOB** 05/23/1956
Client Order # R1056575	**Account Information**			**Report Notes**
Collected 11/02/2012 06:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 11/02/2012 19:55				

Test	Flag	Results	Unit	Reference Value

>> Accession R1056575 - Continued From Previous Page <<
>> Do Not Discard <<

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
TEST,IMPLEMENTATION TESTING	11/02/2012 06:00	Final
Page 2 of 2		** End of Report **

* Report times for Mayo performed tests are CST/CDT